Share Email Print

Proceedings Paper

Laboratory and clinical experience with neodymium:YAG laser prostatectomy
Author(s): John N. Kabalin M.D.
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Since 1991, we have undertaken extensive laboratory and clinical studies of the Neodymium:YAG (Nd:YAG) laser for surgical treatment of bladder outlet obstruction due to prostatic enlargement or benign prostatic hyperplasia (BPH). Side-firing optical fibers which emit a divergent, relatively low energy density Nd:YAG laser beam produce coagulation necrosis of obstructing periurethral prostate tissue, followed by gradual dissolution and slough in the urinary stream. Laser-tissue interactions and Nd:YAG laser dosimetry for prostatectomy have been studied in canine and human prostate model systems, enhancing clinical application. Ongoing studies examine comparative Nd:YAG laser dosimetry for various beam configurations produced by available side-firing optical fibers and continue to refine operative technique. We have documented clinical outcomes of Nd:YAG laser prostatectomy in 230 consecutive patients treated with the UrolaseTM side-firing optical fiber. Nd:YAG laser coagulation the prostate produces a remarkably low acute morbidity profile, with no significant bleeding or fluid absorption. No postoperative incontinence has been produced. Serial assessments of voiding outcomes over more than 3 years of followup show objective and symptomatic improvement following Nd:YAG laser prostatectomy which is comparable to older but more morbid electrosurgical approaches. Nd:YAG laser prostatectomy is a safe, efficacious, durable and cost-effective treatment for BPH.

Paper Details

Date Published: 17 May 1996
PDF: 14 pages
Proc. SPIE 2671, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VI, (17 May 1996); doi: 10.1117/12.240018
Show Author Affiliations
John N. Kabalin M.D., Stanford Univ. School of Medicine (United States)

Published in SPIE Proceedings Vol. 2671:
Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VI
C. Thomas Vangsness M.D.; Kenneth Eugene Bartels D.V.M.; Lawrence S. Bass M.D.; Graham M. Watson M.D.; R. Rox Anderson M.D.; R. Rox Anderson M.D.; Royice B. Everett; Douglas E. Ott M.D.; Reza S. Malek M.D.; Rodney A. White M.D.; Lloyd P. Tate V.D.M.; Aaron P. Perlmutter M.D., Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?